{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:16:56Z","timestamp":1790669816160,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":1201,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvsvenous.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery: Venous and Lymphatic Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jvsv.2021.04.016","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T12:37:36Z","timestamp":1620304656000},"page":"1568-1576.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-6897","authenticated-orcid":false,"given":"Christos","family":"Karathanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petroula","family":"Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Spanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kouvelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Brotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miltiadis","family":"Matsagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Giannoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvsv.2021.04.016_bib1","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1182\/blood-2009-07-199174","article-title":"How I treat postthrombotic syndrome","volume":"114","author":"Kahn","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jvsv.2021.04.016_bib2","first-page":"423","article-title":"The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients","volume":"82","author":"Prandoni","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.jvsv.2021.04.016_bib3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2352-3026(15)00248-3","article-title":"Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5 year follow-up results of an open label, randomized controlled trial","volume":"3","author":"Haig","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jvsv.2021.04.016_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11936-012-0224-3","article-title":"The postthrombotic syndrome: a 2012 therapeutic update","volume":"15","author":"Galanaud","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jvsv.2021.04.016_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0022-4804(77)90030-0","article-title":"The socioeconomic effects of an iliofemoral venous thrombosis","volume":"22","author":"O\u2019Donnell","year":"1977","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jvsv.2021.04.016_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1538-7836.2009.03294.x","article-title":"Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization","volume":"7","author":"Kahn","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl","key":"10.1016\/j.jvsv.2021.04.016_bib8","doi-asserted-by":"crossref","first-page":"195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jvsv.2021.04.016_bib9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/jth.12127","article-title":"The history and historical treatments of deep vein thrombosis","volume":"11","author":"Galanaud","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1538-7836.2005.01333.x","article-title":"Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome","volume":"3","author":"van Dongen","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib11","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1538-7836.2012.04872.x","article-title":"Risk of postthrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study","volume":"10","author":"Chitsike","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor\u2019s choice \u2013 European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvsv.2021.04.016_bib13","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The post-thrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jvsv.2021.04.016_bib14","first-page":"CD002783","article-title":"Thrombolysis for acute deep vein thrombosis","volume":"11","author":"Watson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvsv.2021.04.016_bib15","first-page":"4152","article-title":"Efficacy and safety of catheter-directed thrombolysis in preventing post-thrombotic syndrome: a meta-analysis","volume":"11","author":"Alhazmi","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jvsv.2021.04.016_bib16","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1177\/1076029617739703","article-title":"Catheter-directed thrombolysis versus standard anticoagulation for acute lower extremity deep vein thrombosis: a meta-analysis of clinical trials","volume":"24","author":"Lu","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib17","doi-asserted-by":"crossref","first-page":"0204594","DOI":"10.1371\/journal.pone.0204594","article-title":"Effects of thrombolysis on outcomes of patients with deep venous thrombosis: an updated meta-analysis","volume":"13","author":"Xing","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jvsv.2021.04.016_bib18","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jvsv.2021.04.016_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jvsv.2021.04.016_bib20","author":"Wells"},{"key":"10.1016\/j.jvsv.2021.04.016_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000051263","article-title":"Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials","volume":"12","author":"Oremus","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.jvsv.2021.04.016_bib22","first-page":"40","article-title":"An R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R\u00a0News"},{"key":"10.1016\/j.jvsv.2021.04.016_bib23","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Software"},{"key":"10.1016\/j.jvsv.2021.04.016_bib24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1160\/TH16-01-0041","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis: a post-hoc analysis","volume":"116","author":"Cheung","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2017.05.029","article-title":"Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome","volume":"157","author":"Jeraj","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jvsv.2021.04.016_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1076029618758955","article-title":"Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism","volume":"24","author":"Coleman","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.amjmed.2018.01.041","article-title":"Rivaroxaban vs warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism","volume":"131","author":"S\u00f8gaard","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jvsv.2021.04.016_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.thromres.2018.01.013","article-title":"Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome","volume":"163","author":"Utne","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jvsv.2021.04.016_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.surg.2019.05.030","article-title":"Comparison of the recanalization rate and post-thrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin","volume":"166","author":"de Athayde Soares","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.jvsv.2021.04.016_bib30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11739-019-02215-z","article-title":"The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants","volume":"15","author":"Prandoni","year":"2020","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jvsv.2021.04.016_bib31","doi-asserted-by":"crossref","first-page":"106608","DOI":"10.1016\/j.vph.2019.106608","article-title":"Low prevalence of post-thrombotic syndrome in patients treated with rivaroxaban","volume":"124","author":"Ferreira","year":"2020","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.jvsv.2021.04.016_bib32","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvsv.2021.04.016_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"Ageno","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jvsv.2021.04.016_bib34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1160\/TH16-03-0209","article-title":"Rivaroxaban for the treatment of venous thromboembolism. The Swiss Venous Thromboembolism Registry (SWIVTER)","volume":"116","author":"Kucher","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib35","first-page":"1","article-title":"Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study","volume":"13","author":"Larsen","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jvsv.2021.04.016_bib36","doi-asserted-by":"crossref","first-page":"e0144856","DOI":"10.1371\/journal.pone.0144856","article-title":"Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"10","author":"Cohen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jvsv.2021.04.016_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11239-014-1102-5","article-title":"Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism","volume":"39","author":"Mantha","year":"2015","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jvsv.2021.04.016_bib38","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2352-3026(18)30191-1","article-title":"Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis","volume":"6","author":"Dawwas","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jvsv.2021.04.016_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1538-7836.2004.01106.x","article-title":"Vein abnormalities and the post-thrombotic syndrome","volume":"3","author":"Prandoni","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib40","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1055\/s-0038-1666859","article-title":"Predicting post-thrombotic syndrome with ultrasonographic follow-up after deep vein thrombosis: a systematic review and meta-analysis","volume":"118","author":"Dronkers","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib41","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jvir.2017.03.031","article-title":"Insufficient recanalization of thrombotic venous occlusion and risk for postthrombotic syndrome","volume":"28","author":"Jeraj","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.jvsv.2021.04.016_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2017.03.022","article-title":"Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants","volume":"153","author":"Prandoni","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jvsv.2021.04.016_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S0392-9590.17.03894-9","article-title":"Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again?","volume":"37","author":"Ramacciotti","year":"2018","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2021.04.016_bib44","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1538-7836.2012.04806.x","article-title":"Prevention of post-thrombotic syndrome: a case for new oral anticoagulant drugs or for heparins?","volume":"10","author":"Baglin","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11239-007-0108-7","article-title":"New oral Xa and IIa inhibitors: updates on clinical trial results","volume":"25","author":"Haas","year":"2008","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jvsv.2021.04.016_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jvsv.2021.04.016_bib47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","article-title":"Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran","volume":"142","author":"Ellinghaus","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jvsv.2021.04.016_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2016.06.008","article-title":"Rivaroxaban improves patency and decrease inflammation in a mouse model of catheter thrombosis","volume":"144","author":"Terry","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jvsv.2021.04.016_bib49","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2012.04798.x","article-title":"Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome","volume":"10","author":"Bouman","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jvsv.2021.04.016_bib50","doi-asserted-by":"crossref","first-page":"e42269","DOI":"10.1371\/journal.pone.0042269","article-title":"Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis","volume":"7","author":"Erkens","year":"2012","journal-title":"PLoS One"}],"container-title":["Journal of Vascular Surgery: Venous and Lymphatic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213333X21002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213333X21002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:02:52Z","timestamp":1761980572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213333X21002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2213333X21002122"],"URL":"https:\/\/doi.org\/10.1016\/j.jvsv.2021.04.016","relation":{},"ISSN":["2213-333X"],"issn-type":[{"value":"2213-333X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery: Venous and Lymphatic Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvsv.2021.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the Society for Vascular Surgery. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}